Tiziana Life Sciences Ltd. (TLSA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.97

From 52W high−60.45%

Volume413337.00

Market cap$115.25M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$0.97

From 52W high

−60.45%

Volume

413337.00

Market cap

$115.25M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.3x

P/E (TTM)

—

RSI (14)

45.6

MomentumView details →

1D Return

−6.64%

YTD Return

−37.71%

SummaryUpdated Dec 1, 2025

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a biotechnology company founded in 1998 and headquartered in London, United Kingdom. The company went public on November 20, 2018, and focuses on discovering and developing therapeutic molecules to treat human diseases in oncology and immunology. As a clinical-stage biotechnology firm, Tiziana operates without generating revenue from product sales, instead relying on research and development activities to advance its pipeline of experimental treatments through various stages of clinical trials.

Ask drillr about Tiziana Life Sciences Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−6.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2216.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

−160.34%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−2.06%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−45.45%

EBITDA YoY

+27.75%

MomentumView details →

1D Return

−6.64%

YTD Return

−37.71%

1Y Return

−49.01%

RSI (14)

45.6

vs 50D SMA

−9.15%

vs 200D SMA

−28.42%

Capital & dividendView details →

Debt/Equity

8.77x

Current Ratio

0.76x

Quick Ratio

0.76x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.22

EPS Surprise

−100.31%

Beats (12Q)

1/12

Next Q EPS Est

—

Avg Surprise (4Q)

−234.29%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−34.95M

Op. CF (TTM)

−14.07M

Next earningsOct 7, 2026 →

Latest newsMore news →

Tiziana Life Sciences announced it will present Phase 2a BANYAN trial data for intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday.27d ago

Similar companies

Coya Therapeutics, Inc.COYA Genelux CorporationGNLX Milestone Pharmaceuticals Inc.MIST PMV Pharmaceuticals, Inc.PMVP Aardvark Therapeutics, Inc. Common StockAARD Black Diamond Therapeutics, Inc.BDTX Find similar companies →

Latest newsMore news →

Tiziana Life Sciences signed a memorandum of understanding with King Abdullah International Medical Research Center and partners to support a planned clinical trial of intranasal foralumab combined with anti-CD20 therapy in relapsing-remitting multiple sclerosis patients.3d ago Tiziana Life Sciences announced it will present Phase 2a BANYAN trial data for intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday.27d ago Tiziana Life Sciences announced promising quantitative PET imaging results from the third patient in its Phase 2 clinical trial for a rare neurodegenerative condition, showing reduced neuroinflammation.51d ago